Canakinumab, a human anti-IL1β monoclonal antibody developed by Novartis, has evident antitumor effects against NSCLC [189,190] and is currently being tested in clinical trials for triple-negative BC, CRC, metastatic melanoma and PC treatment. This evidence concerns the gene IL1B and pachyonychia congenita.